Login
Register
Submit a Paper
Propose a Special lssue
Open Access
ARTICLE
Tadalafil: a new agent for erectile dysfunction
Department of Surgery, Division of Urology, St. Joseph’s Health Centre, London, Ontario, Canada
Address correspondence to Dr. Gerald B. Brock, St. Joseph’s
Health Centre, 268 Grosvenor Street, Urology Department,
London, ON N6A 4V2 Canada
Canadian Journal of Urology 2003, 10(Suppl.1), 17-22.
Download PDFAbstract
Oral phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction are preferred by most men, and are recommended in guidelines as first-line therapy, because of convenience, high efficacy, and low rates of side effects. Tadalafil (Cialis™) is a new agent that has been studied in different patient populations. It has a different molecular structure than other PDE5 inhibitors, and a different pharmacologic profile that provides a longer period of effectiveness than other agents. This article will review clinical trials on tadalafil, to provide a comprehensive overview of its efficacy and safety.Keywords
erectile dysfunction, tadalafil, efficacy, pharmacology
Cite This Article
APA Style
Brock, G.B. (2003). Tadalafil: a new agent for erectile dysfunction. Canadian Journal of Urology, 10(Suppl.1), 17–22.
Vancouver Style
Brock GB. Tadalafil: a new agent for erectile dysfunction. Can J Urology. 2003;10(Suppl.1):17–22.
IEEE Style
G.B. Brock, “Tadalafil: a new agent for erectile dysfunction,” Can. J. Urology, vol. 10, no. Suppl.1, pp. 17–22, 2003.
Copyright © 2003 The Author(s). Published by Tech Science Press.This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloads
Citation Tools
